[A18-18] Cabozantinib (renal cell carcinoma) - Second Addendum to Commission A17-56
Last updated 05.04.2018
Commission awarded on 13.03.2018 by the Federal Joint Committee (G-BA).
Adults with advanced renal cell carcinoma after targeted therapy against vascular endothelial growth factor (VEGF)
No change in the conclusion compared with A17-56
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-37||Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A17-56||Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|